The SMi Group is proud to announce the return of the 12th annual ADMET conference taking place in London on the 12th - 13th June 2017.
Join our expert speaker panel at the 12th annual ADMET conference for yet another successful run! Presenting new developments, case studies and challenges in the areas of DMPK. PBPK, PKPD, in vivo/ in vitro/ in silico, transporters, hazards and safety assessment, ADMET modelling and many more!
This event will explore ADMET technologies which determine properties of a drug candidate in the preclinical stage of drug discovery, structure based prediction of ADME properties, PK/PD modelling to validate drug targets and toxicity and many more.
ADMET 2017 will provide a series of practical case studies delivered by leading industry experts that will provide executives with useful tools and best practices to:
Predict drug design interaction
Evaluate drug design interaction
Use a population pharmacokinetic approach to assess DDI
Review the structure based prediction of ADME properties
Learn about In-Vivo drug-drug interaction
Optimise human ADMET studies to assess clinically-relevant drug bioavailability
Gain insight into PK/PD modelling to validate drug targets and toxicity
FEATURED SPEAKERS:
Ajit Narang, Senior Scientist, Genentech
Andreas Reichel, VP, Head Research Pharmacokinetics, Bayer
Carl Petersson, Associate Director Drug Disposition, Merck KGaA
Eric Blomme, Vice President Preclinical Safety, AbbVie
Handan He, Director, Section Head, Nonclinical PK/PD, Novartis
Jackie Bloomer, Director, IVIVT, PTS, GSK
Kiyoyuki Omoto, Scientist, Associate Research Fellow, Pfizer
Kunal Taskar, Senior Investigator and Associate Fellow, GSK
Laurent Salphati, Principal Scientist, Genentech
Matthias Wittwer, Laboratory Head DMPK-BANP-NCPK, Bayer
Na Li, Senior Staff Scientist, Corning
Rob Young, Senior Scientific Investigator and GSK Associate Fellow, GSK
Join our expert speaker panel at the 12th annual ADMET conference for yet another successful run! Presenting new developments, case studies and challenges in the areas of DMPK. PBPK, PKPD, in vivo/ in vitro/ in silico, transporters, hazards and safety assessment, ADMET modelling and many more!
This event will explore ADMET technologies which determine properties of a drug candidate in the preclinical stage of drug discovery, structure based prediction of ADME properties, PK/PD modelling to validate drug targets and toxicity and many more.
ADMET 2017 will provide a series of practical case studies delivered by leading industry experts that will provide executives with useful tools and best practices to:
Predict drug design interaction
Evaluate drug design interaction
Use a population pharmacokinetic approach to assess DDI
Review the structure based prediction of ADME properties
Learn about In-Vivo drug-drug interaction
Optimise human ADMET studies to assess clinically-relevant drug bioavailability
Gain insight into PK/PD modelling to validate drug targets and toxicity
FEATURED SPEAKERS:
Ajit Narang, Senior Scientist, Genentech
Andreas Reichel, VP, Head Research Pharmacokinetics, Bayer
Carl Petersson, Associate Director Drug Disposition, Merck KGaA
Eric Blomme, Vice President Preclinical Safety, AbbVie
Handan He, Director, Section Head, Nonclinical PK/PD, Novartis
Jackie Bloomer, Director, IVIVT, PTS, GSK
Kiyoyuki Omoto, Scientist, Associate Research Fellow, Pfizer
Kunal Taskar, Senior Investigator and Associate Fellow, GSK
Laurent Salphati, Principal Scientist, Genentech
Matthias Wittwer, Laboratory Head DMPK-BANP-NCPK, Bayer
Na Li, Senior Staff Scientist, Corning
Rob Young, Senior Scientific Investigator and GSK Associate Fellow, GSK
